This website has changed. We hope you can find what you need easily, but items have moved around. If you have trouble finding what you are looking for please let us know.

Contact us

Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004-2020


New Zealand (Aotearoa) experienced a Neisseria menin-gitidis serogroup B epidemic during 1991-2006, and inci-dence remains twice that of other high-income countries. We reviewed clinical, laboratory, and immunization data for children <15 years of age with laboratory-confirmed invasive meningococcal disease in Auckland, New Zea-land, during January 1, 2004-December 31, 2020. Of 319 cases in 318 children, 4.1% died, and 23.6% with follow-up data experienced sequelae. Children of Maori and Pacific ethnicity and those living in the most deprived areas were overrepresented. Eighty-one percent were positive for N. meningitidis serogroup B, 8.6% for sero-group W, 6.3% for serogroup C, and 3.7% for serogroup Y. Seventy-nine percent had bacteremia, and 63.9% had meningitis. In New Zealand, Maori and Pacific children are disproportionately affected by this preventable dis-ease. N. meningitidis serogroup B vaccine should be in-cluded in the New Zealand National Immunization Sched-ule to address this persistent health inequity.

view journal